1. Home
  2. PRME vs GUT Comparison

PRME vs GUT Comparison

Compare PRME & GUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

SELL

Current Price

$4.23

Market Cap

526.0M

Sector

Health Care

ML Signal

SELL

Logo Gabelli Utility Trust (The)

GUT

Gabelli Utility Trust (The)

SELL

Current Price

$5.20

Market Cap

519.5M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
PRME
GUT
Founded
2019
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
526.0M
519.5M
IPO Year
2022
1999

Fundamental Metrics

Financial Performance
Metric
PRME
GUT
Price
$4.23
$5.20
Analyst Decision
Buy
Analyst Count
13
0
Target Price
★ $7.03
N/A
AVG Volume (30 Days)
★ 5.5M
325.5K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
★ 10.93%
EPS Growth
★ 18.18
N/A
EPS
N/A
★ N/A
Revenue
★ $4,632,000.00
N/A
Revenue This Year
$18.58
N/A
Revenue Next Year
$23.34
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 55.28
N/A
52 Week Low
$2.67
$5.03
52 Week High
$5.91
$7.07

Technical Indicators

Market Signals
Indicator
PRME
GUT
Relative Strength Index (RSI) 51.32 35.69
Support Level $2.94 $5.03
Resistance Level $4.80 $6.36
Average True Range (ATR) 0.53 0.13
MACD -0.08 0.02
Stochastic Oscillator 22.25 18.37

Price Performance

Historical Comparison
PRME
GUT

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About GUT Gabelli Utility Trust (The)

Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.

Share on Social Networks: